omniture

The Highest Ever Bioavailable Curcumin Will Make its Debut in Europe

2014-11-25 17:29 1856

TOKYO, Nov. 25, 2014 /PRNewswrie/ -- Theravalues Corporation is proud to announce the launching of Theracurmin® Super for the European market at Hi Europe 2014 (Dec. 2-4, Amsterdam).

It is the highest ever bioavailable curcumin, with a combination of amorphous (non-crystal) technology and ingredients approved by European regulations.

Curcumin is a yellow pigment present in the spice turmeric (Curcuma longa) that has been associated with antioxidant, anti-inflammatory, anticancer, antiviral and antibacterial activities.

Despite its range of reported pharmacological effects, curcumin is limited in its clinical applicability by its low bioavailability during oral administration.

The current curcumin product from Theravalues, Theracurmin®, proved 27 times higher bioavailability than ordinary curcumin powder. It has been studied in many human clinical trials over the world and obtained many significant positive results. (Examples as below.)

Major publishing of the clinical trials

Osteoarthritis

 

Significant decrease of dependency on the NSAIDs

 

Kyoto Medical Center

 

Atherosclerosis

 

Improvement of carotid artery stiffness and other functions

 

Tsukuba University

 

Heart failure

 

Improvement of diastolic dysfunction

 

Kyoto Medical Center, et al.

 

Periodontal disease

 

Significantly reduced pocket depth

 

Tokyo Medical and Dental Univ.

 

Hepatic function

 

Significantly improved γGTD, GTP, GOT

 

Takanawa Medical Clinic

 

Theracurmin® Super indicates twice higher bioavailability than Theracurmin® under the double-blind cross-over human clinical trial.

With its extraordinary high bioavailability, Theracurmin® Super will make a huge contribution to treating and preventing a number of diseases in many countries, where aging populations rapidly grow.

Theravalues Corporation will exhibit at Hi Europe 2014 (Stand K90).

A seminar on Theracurmin® Super will also be provided on December 3rd at Hi Europe as follows;

  1. 14:00-14:30 Theracurmin® and Theracurmin® Super; The Most Advanced Form of Curcumin in Bioavailability And Efficacy in Clinical Trials by Tadashi Hashimoto, President, Theravalues Corporation
  2. 14:30-14:55 Major findings from the Pancreatic Clinical Trial by Using Theracurmin®, by Dr. Masashi Kanai, Kyoto University

http://www.figlobal.com/hieurope/features/show-features/ingredients-innovation-theatre?cid=iN_ema_nws_vis_11nov2014_informer46#Day2Session08

About Theravalues

Theravalues Corporation (Kioicho Bldg. 1F, 3-12 Kioicho, Chiyoda-ku, Tokyo 102-0094 Japan) is a leading biotechnology innovator in the health and supplement industry. Based in Tokyo, Japan, it endeavors to offer value-driven consumer products and pharmaceuticals. Its major product, Theracrumin® - one of the most advanced forms of curcumin in the marketplace, is used in a variety of food and beverage segments and dietary supplements in Japan, North America, and many Asian countries.

For more information contact:

Marie Kanatani
Tel: +81-3-3234-7677
Email: mkanatani@theravalues.com

Source: Theravalues Corporation